Literature DB >> 6252138

Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function.

J P Fillastre, A Leroy, G Humbert, M Godin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6252138     DOI： 10.1093/jac/6.suppl_a.103

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  11 in total

1.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

2.  Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function.

Authors:  F Bressolle; J Brès; G Mourad
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

3.  Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation.

Authors:  Jinju Guk; Antoine Bridier-Nahmias; Mélanie Magnan; Nathalie Grall; Xavier Duval; Olivier Clermont; Etienne Ruppé; Camille d'Humières; Olivier Tenaillon; Erick Denamur; France Mentré; Jérémie Guedj; Charles Burdet
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-05-18

4.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

5.  Clinical pharmacology of cefotaxime in pediatric patients.

Authors:  D A Kafetzis; D C Brater; J Kanarios; C A Sinaniotis; C J Papadatos
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

6.  Pharmacokinetics of cefotaxime and desacetylcefotaxime in patients with liver disease.

Authors:  R J Ko; F R Sattler; S Nichols; E Akriviadis; B Runyon; M Appleman; J L Cohen; R T Koda
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

8.  Cefotaxime pharmacokinetics and treatment of meningitis in neonates.

Authors:  R F Jacobs; G L Kearns
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

9.  Elimination kinetics of ceftizoxime in humans with and without renal insufficiency.

Authors:  M Ohkawa; A Okasho; T Sugata; K Kuroda
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

10.  Randomized comparative trial with ceftizoxime and cefotaxime in urinary tract infections.

Authors:  M Tripi; M Pavone-Macaluso; A Giammanco; G Carella
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.